225 related articles for article (PubMed ID: 33148061)
21. Efficacy and safety of adalimumab as the first and second biologic agent in juvenile idiopathic arthritis: the German Biologics JIA Registry.
Schmeling H; Minden K; Foeldvari I; Ganser G; Hospach T; Horneff G
Arthritis Rheumatol; 2014 Sep; 66(9):2580-9. PubMed ID: 24942886
[TBL] [Abstract][Full Text] [Related]
22. Bayesian comparative effectiveness study of four consensus treatment plans for initial management of systemic juvenile idiopathic arthritis: FiRst-Line Options for Systemic juvenile idiopathic arthritis Treatment (FROST).
Nigrovic PA; Beukelman T; Tomlinson G; Feldman BM; Schanberg LE; Kimura Y;
Clin Trials; 2018 Jun; 15(3):268-277. PubMed ID: 29542334
[TBL] [Abstract][Full Text] [Related]
23. Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter study.
Ilowite N; Porras O; Reiff A; Rudge S; Punaro M; Martin A; Allen R; Harville T; Sun YN; Bevirt T; Aras G; Appleton B
Clin Rheumatol; 2009 Feb; 28(2):129-37. PubMed ID: 18766426
[TBL] [Abstract][Full Text] [Related]
24. Anakinra for the treatment of rheumatoid arthritis: a safety evaluation.
Ramírez J; Cañete JD
Expert Opin Drug Saf; 2018 Jul; 17(7):727-732. PubMed ID: 29883212
[TBL] [Abstract][Full Text] [Related]
25. Impact of IL1RN Variants on Response to Interleukin-1 Blocking Therapy in Systemic Juvenile Idiopathic Arthritis.
Hinze C; Fuehner S; Kessel C; Wittkowski H; Lainka E; Baehr M; Hügle B; Haas JP; Ganser G; Weißbarth-Riedel E; Jansson A; Foell D
Arthritis Rheumatol; 2020 Mar; 72(3):499-505. PubMed ID: 31599092
[TBL] [Abstract][Full Text] [Related]
26. Safety and efficacy of etanercept in children with juvenile idiopathic arthritis below the age of 2 years.
Windschall D; Müller T; Becker I; Horneff G
Rheumatol Int; 2015 Apr; 35(4):613-8. PubMed ID: 25208527
[TBL] [Abstract][Full Text] [Related]
27. Anakinra in children and adults with Still's disease.
Vastert SJ; Jamilloux Y; Quartier P; Ohlman S; Osterling Koskinen L; Kullenberg T; Franck-Larsson K; Fautrel B; de Benedetti F
Rheumatology (Oxford); 2019 Nov; 58(Suppl 6):vi9-vi22. PubMed ID: 31769856
[TBL] [Abstract][Full Text] [Related]
28. Anakinra treatment in macrophage activation syndrome: a single center experience and systemic review of literature.
Sönmez HE; Demir S; Bilginer Y; Özen S
Clin Rheumatol; 2018 Dec; 37(12):3329-3335. PubMed ID: 29663156
[TBL] [Abstract][Full Text] [Related]
29. Recombinant Interleukin-1 Receptor Antagonist Is an Effective First-Line Treatment Strategy in New-Onset Systemic Juvenile Idiopathic Arthritis, Irrespective of HLA-DRB1 Background and IL1RN Variants.
Erkens RGA; Calis JJA; Verwoerd A; De Roock S; Ter Haar NM; Den Engelsman G; Van der Veken LT; Ernst RF; Van Deutekom HWM; Pickering A; Scholman RC; Jansen MHA; Swart JF; Sinha R; Roth J; Schulert GS; Grom AA; Van Loosdregt J; Vastert SJ
Arthritis Rheumatol; 2024 Jan; 76(1):119-129. PubMed ID: 37471469
[TBL] [Abstract][Full Text] [Related]
30. Pharmacovigilance in juvenile idiopathic arthritis patients treated with biologic or synthetic drugs: combined data of more than 15,000 patients from Pharmachild and national registries.
Swart J; Giancane G; Horneff G; Magnusson B; Hofer M; Alexeeva Е; Panaviene V; Bader-Meunier B; Anton J; Nielsen S; De Benedetti F; Kamphuis S; Staņēviča V; Tracahana M; Ailioaie LM; Tsitsami E; Klein A; Minden K; Foeldvari I; Haas JP; Klotsche J; Horne AC; Consolaro A; Bovis F; Bagnasco F; Pistorio A; Martini A; Wulffraat N; Ruperto N;
Arthritis Res Ther; 2018 Dec; 20(1):285. PubMed ID: 30587248
[TBL] [Abstract][Full Text] [Related]
31. Anakinra and hepatotoxicity in pediatric rheumatology: a case series.
Martins FR; Azevedo AC; Ganhão S; Aguiar F; Rodrigues M; Brito I
Pediatr Rheumatol Online J; 2023 Oct; 21(1):112. PubMed ID: 37803456
[TBL] [Abstract][Full Text] [Related]
32. Inflammatory bowel disease following anti-interleukin-1-treatment in systemic juvenile idiopathic arthritis.
Hügle B; Speth F; Haas JP
Pediatr Rheumatol Online J; 2017 Mar; 15(1):16. PubMed ID: 28288653
[TBL] [Abstract][Full Text] [Related]
33. Effectiveness and safety of a second and third biological agent after failing etanercept in juvenile idiopathic arthritis: results from the Dutch National ABC Register.
Otten MH; Prince FH; Anink J; Ten Cate R; Hoppenreijs EP; Armbrust W; Koopman-Keemink Y; van Pelt PA; Kamphuis S; Gorter SL; Dolman KM; Swart JF; van den Berg JM; Wulffraat NM; van Rossum MA; van Suijlekom-Smit LW
Ann Rheum Dis; 2013 May; 72(5):721-7. PubMed ID: 22730374
[TBL] [Abstract][Full Text] [Related]
34. Short-term outcomes in patients with systemic juvenile idiopathic arthritis treated with either tocilizumab or anakinra.
Kearsley-Fleet L; Beresford MW; Davies R; De Cock D; Baildam E; Foster HE; Southwood TR; Thomson W; Hyrich KL
Rheumatology (Oxford); 2019 Jan; 58(1):94-102. PubMed ID: 30137641
[TBL] [Abstract][Full Text] [Related]
35. IL-6 blockade in systemic juvenile idiopathic arthritis - achievement of inactive disease and remission (data from the German AID-registry).
Bielak M; Husmann E; Weyandt N; Haas JP; Hügle B; Horneff G; Neudorf U; Lutz T; Lilienthal E; Kallinich T; Tenbrock K; Berendes R; Niehues T; Wittkowski H; Weißbarth-Riedel E; Heubner G; Oommen P; Klotsche J; Foell D; Lainka E
Pediatr Rheumatol Online J; 2018 Apr; 16(1):22. PubMed ID: 29622022
[TBL] [Abstract][Full Text] [Related]
36. Physician practices for withdrawal of medications in inactive systemic juvenile arthritis, Childhood Arthritis and Rheumatology Research Alliance (CARRA) survey.
Shenoi S; Nanda K; Schulert GS; Bohnsack JF; Cooper AM; Edghill B; Gillispie-Taylor MC; Goldberg B; Halyabar O; Mason TG; Ronis T; Schneider R; Vehe RK; Onel K;
Pediatr Rheumatol Online J; 2019 Jul; 17(1):48. PubMed ID: 31331351
[TBL] [Abstract][Full Text] [Related]
37. The efficacy and safety of interleukin-1-receptor antagonist anakinra in the treatment of systemic juvenile idiopathic arthritis.
Swart JF; Barug D; Möhlmann M; Wulffraat NM
Expert Opin Biol Ther; 2010 Dec; 10(12):1743-52. PubMed ID: 20979564
[TBL] [Abstract][Full Text] [Related]
38. Effectiveness of first-line treatment with recombinant interleukin-1 receptor antagonist in steroid-naive patients with new-onset systemic juvenile idiopathic arthritis: results of a prospective cohort study.
Vastert SJ; de Jager W; Noordman BJ; Holzinger D; Kuis W; Prakken BJ; Wulffraat NM
Arthritis Rheumatol; 2014 Apr; 66(4):1034-43. PubMed ID: 24757154
[TBL] [Abstract][Full Text] [Related]
39. Trends in prescription of biological agents and outcomes of juvenile idiopathic arthritis: results of the Dutch national Arthritis and Biologics in Children Register.
Otten MH; Anink J; Prince FH; Twilt M; Vastert SJ; ten Cate R; Hoppenreijs EP; Armbrust W; Gorter SL; van Pelt PA; Kamphuis SS; Dolman KM; Swart JF; van den Berg JM; Koopman-Keemink Y; van Rossum MA; Wulffraat NM; van Suijlekom-Smit LW
Ann Rheum Dis; 2015 Jul; 74(7):1379-86. PubMed ID: 24641940
[TBL] [Abstract][Full Text] [Related]
40. Impact of biologics on disease course in systemic onset juvenile idiopathic arthritis.
Baris HE; Anderson E; Sozeri B; Dedeoglu F
Clin Rheumatol; 2018 Dec; 37(12):3263-3273. PubMed ID: 30238379
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
